Surprisingly, a 2024 case report documented complete and sustained remission of psoriasis following CD19 Chimeric antigen receptor T-cell (CAR-T) cell therapy targeting B cells, with no relapse observed over 3.5 years of follow-up [173]. This evidence concerns the gene CD19 and psoriasis.